Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium‐223

The objective of this study was to evaluate automated bone scan index (aBSI) as a prognostic biomarker for overall survival (OS) in bone‐metastatic, castration‐resistant prostate cancer (mCRPC) patients treated with radium‐223 (Ra‐223).

[1]  L. Edenbrandt,et al.  Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients , 2019, The Journal of Nuclear Medicine.

[2]  S. Sakamoto,et al.  Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer , 2019, Urologia Internationalis.

[3]  H. Yaegashi,et al.  Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy , 2019, AntiCancer Research.

[4]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[5]  F. Xue,et al.  Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model , 2019, BMC Cancer.

[6]  J. Carles,et al.  Circulating Tumor Cells as a Biomarker of Survival and Response to Radium‐223 Therapy: Experience in a Cohort of Patients With Metastatic Castration‐Resistant Prostate Cancer , 2018, Clinical genitourinary cancer.

[7]  S. Gillessen,et al.  Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium‐223? , 2018, Clinical genitourinary cancer.

[8]  Lars Edenbrandt,et al.  Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA oncology.

[9]  M. Yao,et al.  Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel , 2018, BMC Cancer.

[10]  J. Mortensen,et al.  223Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity , 2017, The Journal of Nuclear Medicine.

[11]  M. Yao,et al.  Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration‐resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate , 2017, Clinical genitourinary cancer.

[12]  S. Takebayashi,et al.  Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer , 2017, Urologia Internationalis.

[13]  L. Edenbrandt,et al.  Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer , 2017, International journal of urology : official journal of the Japanese Urological Association.

[14]  Mattias Ohlsson,et al.  Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. , 2016, European urology focus.

[15]  L. Edenbrandt,et al.  Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study. , 2016, European urology focus.

[16]  C. Parker,et al.  Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. , 2016, European urology.

[17]  L. Edenbrandt,et al.  Bone Scan Index predicts outcome in patients with metastatic hormone‐sensitive prostate cancer , 2016, BJU international.

[18]  S. Larson,et al.  Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide , 2016, EJNMMI Research.

[19]  M. Yao,et al.  Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases , 2016, BMC Cancer.

[20]  N. Hagiwara,et al.  In vivo validation of gated myocardial SPECT imaging for quantification of small hearts: comparison with cardiac MRI , 2016, EJNMMI Research.

[21]  K. Miwa,et al.  Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting , 2015, Annals of Nuclear Medicine.

[22]  L. Edenbrandt,et al.  Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). , 2014, Urologic oncology.

[23]  M. Lomsky,et al.  Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index , 2013, EJNMMI Research.

[24]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[25]  K. Nakajima,et al.  Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases , 2013, Annals of Nuclear Medicine.

[26]  M. Lomsky,et al.  Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy , 2013, EJNMMI Research.

[27]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[28]  H. Shiina,et al.  Prediction of survival benefit using an automated bone scan index in patients with castration‐resistant prostate cancer , 2012, BJU international.

[29]  Mattias Ohlsson,et al.  A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. , 2012, European urology.

[30]  S. Larson,et al.  Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Bjartell,et al.  Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. , 2006, European urology.

[32]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[33]  S M Larson,et al.  A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.

[35]  Gerharddr..  Acute Articular Rheumatism , 1838 .

[36]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.